Next Generation mRNA Vaccinology · 2.PSMA Targeted Therapy for Prostate Cancer · 3.New treatment to lower LDL · 4.In the United States, 1 in 10 people has diabetes, which affects how the body processes food for energy. One possible therapy is a double glucose-dependent insulinotropic polypeptide (GIP) injectable once a week and a glucagon-like peptide receptor (GLP) agonist, whose objective is to control blood sugar. Injected under the skin, GLP-1 and GIP receptors cause the pancreas to release insulin and block the hormone glucagon, limiting blood sugar spikes after a meal. In addition, it slows digestion, which causes people to stay full longer and eat less.
So far, late phase III clinical trials reveal that the treatment significantly reduces hemoglobin A1C in type 2 diabetes and contributes to weight loss, making it the most effective treatment for diabetes and obesity ever developed. More than 50 percent of all menopausal women experience hot flashes, which can persist for an average of seven years. While effective and safe when used properly, hormone therapy involves some risk and not all patients are suitable candidates or prepared to try this treatment option. Fortunately, a new group of non-hormonal drugs, called NK3R antagonists, has emerged as a viable alternative to hormone therapy.
These drugs alter a signaling pathway in the brain that has been linked to the development of hot flashes and, in clinical trials, have shown promise in relieving moderate to severe menopausal hot flashes as effectively as hormones. While additional studies are needed to fully understand the efficacy and safety of these new drugs, it's clear that the next generation of non-hormonal treatments for menopausal hot flashes is on the horizon. About one in 50 Americans, or 5.4 million people, has some form of paralysis. Most patients experience a significant decline in their overall health.
Recently, a team has offered new hope to these patients by taking advantage of implanted brain-computer interface technology to recover lost motor control and allow patients to control digital devices. The technology uses implanted electrodes to collect movement signals from the brain and decode them into movement orders. It has been shown to restore voluntary motor impulses in patients with severe paralysis due to brain, spinal cord, peripheral nerve, or muscle dysfunction. Although interface technology is in its infancy, the FDA has designated the implantable as an “innovative device”, reinforcing the need to bring this technology to the bed of patients who need it most.
For more information on the annual list of the top 10 medical innovations, which includes descriptions, videos and year-by-year comparisons, visit Cleveland Clinic Innovations. Transinstitutional effort to accelerate scientific solutions to stop the national opioid crisis. Learn about participating in clinical trials and where to find them.
